A CRF1 receptor antagonist, NBI 30775/R121919, reduced depression and anxiety scores using patient and clinician ratings without impairing corticotropin and cortisol secretion in patients with MDD (Zobel et al., 2000). The gene discussed is POMC; the disease is major depressive disorder.